Isospec Analytics lands US$366.7K Tech Growth loan from Fondation FIT
What's the deal? The Foundation for Innovation and TechnologyDealroom has a profile for this one. Try Dealroom → has awarded a US$366.7K (≈$493,728) Tech Growth loan to Isospec AnalyticsDealroom has a profile for this one. Try Dealroom →, an EPFLDealroom has a profile for this one. Try Dealroom → spin-off that identifies biological molecules for medical research.
The startup reads molecules like a fingerprint from patient samples — a hundred times faster than existing methods. That helps researchers understand diseases and develop more targeted drugs.
Fellow recipient MYSTONES, an athlete-tracking platform, picked up a smaller US$18.3K Digital Grant.
Why now? The loan builds on Isospec's first Tech Seed loan from the foundation in 2024. With the fresh debt, the 10-person team plans to double its analysis capacity and double revenue by the end of 2026.
Isospec has already run pilot projects, notably with Swiss university hospital CHUVDealroom has a profile for this one. Try Dealroom →.
MYSTONES, meanwhile, is trialling its platform with around 60 athletes. The grant will fund new indicators, a better dashboard, and preparation for first partnerships.
What could go wrong? Doubling capacity and revenue in a single year is steep. Isospec is moving from pilots to scale, where technical and commercial execution gets harder.
MYSTONES faces a fragmented market: athletics remains one of the least digitised sports, and convincing athletes, coaches, and physiotherapists to consolidate onto one tool is no small task.
The signal: Isospec's progression from a 2024 Tech Seed loan to this larger Tech Growth tranche shows the Foundation for Innovation and Technology backing its early-stage bets as they mature, using non-dilutive debt to bridge deep-tech startups from pilot to scale without diluting founders.
Read more: BioAlps
Image credit: "Mass Spectrometry Laboratory (06410488)" by IAEA Imagebank is licensed under CC BY-SA 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by-sa/2.0/.
